Bio-Optronics, the creator of the market-leading Clinical Conductor Clinical Trial Management System (CTMS) announces a new partnership with Synexus, the world’s largest site network organization. This partnership is aimed at improving patient access to modern medicine and improving overall clinical trial efficiency by delivering high numbers of quality patients to clinical trials through the use of a unified CTMS across the entire Synexus network of more than 200 sites in eleven countries worldwide.
“This partnership combines the unique breadth and depth of the Synexus site network with the advanced collaborative trial management tools of Clinical Conductor CTMS in order to bring unparalleled quality, efficiency and profitability to global research operations,” says Max Elbaz, VP of Sales and Marketing at Bio-Optronics.
“As the largest site network in the world, our partnership with Bio-Optronics is important to our future growth. Rolling out Clinical Conductor across our whole organization is the only way we can consistently manage over 200 sites with hundreds of studies”, states Marcin Gondek, Chief Financial Officer at Synexus. “To us, Bio-Optronics are more than just a software vendor, they are a strategic partner who helps us find, manage and care for over 150,000 patients per year”
Both Synexus and Bio-Optronics are attending and sponsoring the 2018 EU Site Solutions Summit in London, England, March 26-27, 2018. Moving forward, Bio-Optronics and Synexus will continue to evolve how global clinical trials are managed across an expanding network of sites around the world.
About Synexus
Synexus is the world’s leading site network for clinical trials, offering unmatched site network capabilities to help biopharmaceutical and contract research organization customers find the right patient for the right trial at the right time. Synexus’ global site network includes more than 200 sites and 1,500 employees spanning 11 countries, offering access to more than 100 million patients in key clinical development markets. Synexus provides data-driven site selection and activation, combined with proven patient engagement and retention expertise across the U.S., Europe and Africa.
For more information visit: www.synexus.com
About Bio-Optronics
Bio-Optronics, the creator of Clinical Conductor CTMS, is a leading software and services company that creates user-focused software and services for healthcare organizations that positively impacts the lives of patients around the world. Clinical Conductor CTMS is an established clinical trial management system designed to help businesses run the world’s best research. Utilized by thousands of research organizations worldwide, Clinical Conductor is designed to simplify and standardize complex research processes for businesses managing and conducting clinical trials.
For more information, call our call center or Sales Executives and visit www.bio-optronics.com or follow @BioOptronics on Twitter or LinkedIn
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.